An updated Cochrane review has found that prostate-specific antigen (PSA) screening probably reduces deaths from prostate cancer — a notable shift from the influential group’s 2013 conclusion that ...

Add Yahoo as a preferred source to see more of our stories on Google. b' Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023 ...

The standard PSA test has anchored prostate cancer screening for decades, but it has a well-known weakness: it flags plenty ...

The understanding of prostate cancer has significantly evolved in the past 15 years. However, many people—including primary care providers—may not be aware of the current guidelines for prostate ...

An elevated PSA reading has long put men in an uncomfortable position: it signals possible prostate cancer, but it is ...

The Stockholm3 model combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors for prostate cancer screening.

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Annual prostate cancer cases are projected to rise from 1.4 million in 2020 to 2.9 million in 2040, and annual deaths to increase by 85% to almost 700,000 over the same timeframe, mainly among men in ...

This is a retrospective study of patients with metastatic Pca, diagnosed at King Hussein Cancer Center, Jordan, between 2006 and 2018. Survival was estimated using the Kaplan-Meier method and compared ...